$LGVN Income Statement | Understand Stock

$LGVN

$1.75 -$0.03 (1.69%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Clinical trial revenue
Contract manufacturing lease revenue
Contract manufacturing revenue
Grant revenue
Total revenues
Cost of revenues
Gross profit
Operating expenses
General and administrative
Research and development
Sales and marketing
Total operating expenses
Loss from operations
Other income and (expense)
Forgiveness of Paycheck Protection Program loan
Interest expense
Lawsuit expense
Other refundable tax credits
Other income, net
Loss on disposal of assets
Other income (expense), net

Basic and diluted net loss per share (in Dollars per share)
Basic and diluted weighted average common shares outstanding (in Shares)
Total other income (expenses), net
Net loss
Dividend attributable to warrant down round feature
Deemed dividend - warrant inducement offers
Net loss attributable to common stockholders
Basic net loss per share
Diluted net loss per share
Basic weighted average common shares outstanding
Diluted weighted average common shares outstanding

Comments